APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroendocrine Tumor Drug

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Neuroendocrine Tumor Drug Market Analysis and Forecast 2026-2032

19 December 2025202 pages

Choose your research edition.

Industry ResearchNeuroendocrine Tumor Drug Industry Research Report 2026133 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroendocrine Tumor Drug Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Neuroendocrine Tumor Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroendocrine Tumor Drug Market Outlook and Growth Opportunities 2026200 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroendocrine Tumor Drug Market Analysis and Forecast 2026-2032202 pages · $4,950 USD

Market perspective

The global Neuroendocrine Tumor Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Neuroendocrine Tumor Drug is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Neuroendocrine Tumor Drug include Exelixis, Inc., Foresee Pharmaceuticals, LLC, Hutchison MediPharma Limited, Intezyne, Inc, INVENT Pharmaceuticals, Inc., Ipsen S.A., Karyopharm Therapeutics, Inc., Lexicon Pharmaceuticals, Inc. and Midatech Pharma Plc ., etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Neuroendocrine Tumor Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Neuroendocrine Tumor Drug, also provides the sales of main regions and countries. Of the upcoming market potential for Neuroendocrine Tumor Drug, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Neuroendocrine Tumor Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Neuroendocrine Tumor Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Neuroendocrine Tumor Drug sales, projected growth trends, production technology, application and end-user industry.

Neuroendocrine Tumor Drug Segment by Company

Exelixis, Inc.

Foresee Pharmaceuticals, LLC

Hutchison MediPharma Limited

Intezyne, Inc

INVENT Pharmaceuticals, Inc.

Ipsen S.A.

Karyopharm Therapeutics, Inc.

Lexicon Pharmaceuticals, Inc.

Midatech Pharma Plc .

Millennium Pharmaceuticals, Inc.

MolMed S.p.A.

Northwest Biotherapeutics, Inc.

OctreoPharm Sciences GmbH

OXiGENE, Inc.

Jiangsu Hengrui Medicine Co., Ltd.

Novartis AG

Eisai

Neuroendocrine Tumor Drug Segment by Type

mTOR Protein Inhibitors

Tyrosine Kinase 3 Inhibitors

Growth Hormone Releasing Factor Antagonists

Somatostatin Receptor Agonists

Somatostatin Receptor Antagonists

Others

Neuroendocrine Tumor Drug Segment by Application

Hospital

Clinic

Others

Neuroendocrine Tumor Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroendocrine Tumor Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroendocrine Tumor Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroendocrine Tumor Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Neuroendocrine Tumor Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Neuroendocrine Tumor Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Neuroendocrine Tumor Drug sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. mTOR Protein Inhibitors Major Manufacturers Table 3. Tyrosine Kinase 3 Inhibitors Major Manufacturers Table 4. Growth Hormone Releasing Factor Antagonists Major Manufacturers Table 5. Somatostatin Receptor Agonists Major Manufacturers Table 6. Somatostatin Receptor Antagonists Major Manufacturers Table 7. Others Major Manufacturers Table 8. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 9. Hospital Major Manufacturers Table 10. Clinic Major Manufacturers Table 11. Others Major Manufacturers Table 12. Neuroendocrine Tumor Drug Industry Trends Table 13. Neuroendocrine Tumor Drug Industry Drivers Table 14. Neuroendocrine Tumor Drug Industry Opportunities and Challenges Table 15. Neuroendocrine Tumor Drug Industry Restraints Table 16. Global Neuroendocrine Tumor Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Neuroendocrine Tumor Drug Revenue by Region (2021-2026) & (US$ Million) Table 18. Global Neuroendocrine Tumor Drug Revenue by Region (2027-2032) & (US$ Million) Table 19. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2021-2026) Table 20. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2027-2032) Table 21. Global Neuroendocrine Tumor Drug Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (W Units) Table 22. Global Neuroendocrine Tumor Drug Sales by Region (2021-2026) & (W Units) Table 23. Global Neuroendocrine Tumor Drug Sales by Region (2027-2032) & (W Units) Table 24. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2021-2026) Table 25. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2027-2032) Table 26. Global Neuroendocrine Tumor Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2021-2026) Table 28. Global Neuroendocrine Tumor Drug Sales by Manufacturers (US$ Million) & (2021-2026) Table 29. Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2021-2026) Table 30. Global Neuroendocrine Tumor Drug Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 31. Global Neuroendocrine Tumor Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 32. Global Neuroendocrine Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters Table 33. Global Neuroendocrine Tumor Drug Manufacturers, Product Type & Application Table 34. Global Neuroendocrine Tumor Drug Manufacturers' Establishment Date Table 35. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 36. Global Neuroendocrine Tumor Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 37. Global Neuroendocrine Tumor Drug Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Neuroendocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 39. Global Neuroendocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 40. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2021-2026) Table 41. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2027-2032) Table 42. Global Neuroendocrine Tumor Drug Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 43. Global Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 44. Global Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 45. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2021-2026) Table 46. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2027-2032) Table 47. Global Neuroendocrine Tumor Drug Price by Type (2021-2026) & (US$/Unit) Table 48. Global Neuroendocrine Tumor Drug Price by Type (2027-2032) & (US$/Unit) Table 49. Global Neuroendocrine Tumor Drug Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 50. Global Neuroendocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 51. Global Neuroendocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 52. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2021-2026) Table 53. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2027-2032) Table 54. Global Neuroendocrine Tumor Drug Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 55. Global Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 57. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2021-2026) Table 58. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2027-2032) Table 59. Global Neuroendocrine Tumor Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Neuroendocrine Tumor Drug Price by Application (2027-2032) & (US$/Unit) Table 61. Exelixis, Inc. Company Information Table 62. Exelixis, Inc. Business Overview Table 63. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 64. Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 65. Exelixis, Inc. Recent Development Table 66. Foresee Pharmaceuticals, LLC Company Information Table 67. Foresee Pharmaceuticals, LLC Business Overview Table 68. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 69. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio Table 70. Foresee Pharmaceuticals, LLC Recent Development Table 71. Hutchison MediPharma Limited Company Information Table 72. Hutchison MediPharma Limited Business Overview Table 73. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 74. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio Table 75. Hutchison MediPharma Limited Recent Development Table 76. Intezyne, Inc Company Information Table 77. Intezyne, Inc Business Overview Table 78. Intezyne, Inc Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 79. Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio Table 80. Intezyne, Inc Recent Development Table 81. INVENT Pharmaceuticals, Inc. Company Information Table 82. INVENT Pharmaceuticals, Inc. Business Overview Table 83. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 84. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 85. INVENT Pharmaceuticals, Inc. Recent Development Table 86. Ipsen S.A. Company Information Table 87. Ipsen S.A. Business Overview Table 88. Ipsen S.A. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 89. Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio Table 90. Ipsen S.A. Recent Development Table 91. Karyopharm Therapeutics, Inc. Company Information Table 92. Karyopharm Therapeutics, Inc. Business Overview Table 93. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 95. Karyopharm Therapeutics, Inc. Recent Development Table 96. Lexicon Pharmaceuticals, Inc. Company Information Table 97. Lexicon Pharmaceuticals, Inc. Business Overview Table 98. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 100. Lexicon Pharmaceuticals, Inc. Recent Development Table 101. Midatech Pharma Plc . Company Information Table 102. Midatech Pharma Plc . Business Overview Table 103. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio Table 105. Midatech Pharma Plc . Recent Development Table 106. Millennium Pharmaceuticals, Inc. Company Information Table 107. Millennium Pharmaceuticals, Inc. Business Overview Table 108. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 110. Millennium Pharmaceuticals, Inc. Recent Development Table 111. MolMed S.p.A. Company Information Table 112. MolMed S.p.A. Business Overview Table 113. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio Table 115. MolMed S.p.A. Recent Development Table 116. Northwest Biotherapeutics, Inc. Company Information Table 117. Northwest Biotherapeutics, Inc. Business Overview Table 118. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 120. Northwest Biotherapeutics, Inc. Recent Development Table 121. OctreoPharm Sciences GmbH Company Information Table 122. OctreoPharm Sciences GmbH Business Overview Table 123. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio Table 125. OctreoPharm Sciences GmbH Recent Development Table 126. OXiGENE, Inc. Company Information Table 127. OXiGENE, Inc. Business Overview Table 128. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 129. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio Table 130. OXiGENE, Inc. Recent Development Table 131. Jiangsu Hengrui Medicine Co., Ltd. Company Information Table 132. Jiangsu Hengrui Medicine Co., Ltd. Business Overview Table 133. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 134. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio Table 135. Jiangsu Hengrui Medicine Co., Ltd. Recent Development Table 136. Novartis AG Company Information Table 137. Novartis AG Business Overview Table 138. Novartis AG Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 139. Novartis AG Neuroendocrine Tumor Drug Product Portfolio Table 140. Novartis AG Recent Development Table 141. Eisai Company Information Table 142. Eisai Business Overview Table 143. Eisai Neuroendocrine Tumor Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 144. Eisai Neuroendocrine Tumor Drug Product Portfolio Table 145. Eisai Recent Development Table 146. North America Neuroendocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 147. North America Neuroendocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 148. North America Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 149. North America Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 150. North America Neuroendocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 151. North America Neuroendocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 152. North America Neuroendocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 153. North America Neuroendocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 154. North America Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 155. North America Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 156. North America Neuroendocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 157. North America Neuroendocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 158. North America Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. North America Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 160. North America Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 161. North America Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 162. North America Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 163. North America Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 164. North America Neuroendocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 165. North America Neuroendocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 166. United States Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 167. Canada Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 168. Europe Neuroendocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 169. Europe Neuroendocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 170. Europe Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 171. Europe Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 172. Europe Neuroendocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 173. Europe Neuroendocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 174. Europe Neuroendocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 175. Europe Neuroendocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 176. Europe Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 177. Europe Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 178. Europe Neuroendocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 179. Europe Neuroendocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 180. Europe Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 181. Europe Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 182. Europe Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 183. Europe Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 184. Europe Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 185. Europe Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 186. Europe Neuroendocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 187. Europe Neuroendocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 188. Germany Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 189. France Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 190. U.K. Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 191. Italy Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 192. Netherlands Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 193. Nordic Countries Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 194. China Neuroendocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 195. China Neuroendocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 196. China Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 197. China Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 198. China Neuroendocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 199. China Neuroendocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 200. China Neuroendocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 201. China Neuroendocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 202. China Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 203. China Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 204. China Neuroendocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 205. China Neuroendocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 206. Asia Neuroendocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 207. Asia Neuroendocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 208. Asia Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 209. Asia Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 210. Asia Neuroendocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 211. Asia Neuroendocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 212. Asia Neuroendocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 213. Asia Neuroendocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 214. Asia Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 215. Asia Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 216. Asia Neuroendocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 217. Asia Neuroendocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 218. Asia Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 219. Asia Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 220. Asia Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 221. Asia Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 222. Asia Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 223. Asia Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 224. Asia Neuroendocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 225. Asia Neuroendocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 226. Japan Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 227. South Korea Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 228. India Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 229. Australia Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 230. China Taiwan Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 231. Southeast Asia Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 232. SAMEA Neuroendocrine Tumor Drug Revenue by Type (2021-2026) & (US$ Million) Table 233. SAMEA Neuroendocrine Tumor Drug Revenue by Type (2027-2032) & (US$ Million) Table 234. SAMEA Neuroendocrine Tumor Drug Sales by Type (2021-2026) & (W Units) Table 235. SAMEA Neuroendocrine Tumor Drug Sales by Type (2027-2032) & (W Units) Table 236. SAMEA Neuroendocrine Tumor Drug Sales Price by Type (2021-2026) & (US$/Unit) Table 237. SAMEA Neuroendocrine Tumor Drug Sales Price by Type (2027-2032) & (US$/Unit) Table 238. SAMEA Neuroendocrine Tumor Drug Revenue by Application (2021-2026) & (US$ Million) Table 239. SAMEA Neuroendocrine Tumor Drug Revenue by Application (2027-2032) & (US$ Million) Table 240. SAMEA Neuroendocrine Tumor Drug Sales by Application (2021-2026) & (W Units) Table 241. SAMEA Neuroendocrine Tumor Drug Sales by Application (2027-2032) & (W Units) Table 242. SAMEA Neuroendocrine Tumor Drug Sales Price by Application (2021-2026) & (US$/Unit) Table 243. SAMEA Neuroendocrine Tumor Drug Sales Price by Application (2027-2032) & (US$/Unit) Table 244. SAMEA Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 245. SAMEA Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 246. SAMEA Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 247. SAMEA Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032) & (W Units) Table 248. SAMEA Neuroendocrine Tumor Drug Sales by Country (2021-2026) & (W Units) Table 249. SAMEA Neuroendocrine Tumor Drug Sales by Country (2027-2032) & (W Units) Table 250. SAMEA Neuroendocrine Tumor Drug Sales Price by Country (2021-2026) & (US$/Unit) Table 251. SAMEA Neuroendocrine Tumor Drug Sales Price by Country (2027-2032) & (US$/Unit) Table 252. Brazil Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 253. Argentina Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 254. Chile Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 255. Colombia Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 256. Peru Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 257. Saudi Arabia Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 258. Israel Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 259. UAE Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 260. Turkey Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 261. Iran Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 262. Egypt Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Table 263. Key Raw Materials Table 264. Raw Materials Key Suppliers Table 265. Neuroendocrine Tumor Drug Distributors List Table 266. Neuroendocrine Tumor Drug Customers List Table 267. Research Programs/Design for This Report Table 268. Authors List of This Report Table 269. Secondary Sources Table 270. Primary Sources List of Figures Figure 1. Neuroendocrine Tumor Drug Image Figure 2. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroendocrine Tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 4. mTOR Protein Inhibitors Image Figure 5. Tyrosine Kinase 3 Inhibitors Image Figure 6. Growth Hormone Releasing Factor Antagonists Image Figure 7. Somatostatin Receptor Agonists Image Figure 8. Somatostatin Receptor Antagonists Image Figure 9. Others Image Figure 10. Global Neuroendocrine Tumor Drug Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 11. Global Neuroendocrine Tumor Drug Market Size Share 2021 VS 2025 VS 2032 Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Neuroendocrine Tumor Drug Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Neuroendocrine Tumor Drug Revenue (2021-2032) & (US$ Million) Figure 17. Global Neuroendocrine Tumor Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Neuroendocrine Tumor Drug Revenue Market Share by Region: 2025 Versus 2032 Figure 19. Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2021-2032) Figure 20. Global Neuroendocrine Tumor Drug Sales (2021-2032) & (W Units) Figure 21. Global Neuroendocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032 (W Units) Figure 22. Global Neuroendocrine Tumor Drug Sales Market Share by Region (2021-2032) Figure 23. US & Canada & Mexico Neuroendocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 24. Europe Neuroendocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 25. China Neuroendocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 26. Asia (Excluding China) Neuroendocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 27. South America, Middle East and Africa Neuroendocrine Tumor Drug Sales YoY (2021-2032) & (W Units) Figure 28. Global Neuroendocrine Tumor Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 29. Global Neuroendocrine Tumor Drug Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 30. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Global Neuroendocrine Tumor Drug Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 32. Global Neuroendocrine Tumor Drug Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 33. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2021-2032) Figure 34. Global Neuroendocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 35. Global Neuroendocrine Tumor Drug Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 36. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2021-2032) Figure 37. Global Neuroendocrine Tumor Drug Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 38. Global Neuroendocrine Tumor Drug Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 39. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2021-2032) Figure 40. Global Neuroendocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 41. Global Neuroendocrine Tumor Drug Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 42. Global Neuroendocrine Tumor Drug Sales Market Share by Application (2021-2032) Figure 43. North America Neuroendocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 44. North America Neuroendocrine Tumor Drug Sales Share by Type (2021-2032) Figure 45. North America Neuroendocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 46. North America Neuroendocrine Tumor Drug Sales Share by Application (2021-2032) Figure 47. North America Neuroendocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 48. North America Neuroendocrine Tumor Drug Sales Share by Country (2021-2032) Figure 49. Europe Neuroendocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 50. Europe Neuroendocrine Tumor Drug Sales Share by Type (2021-2032) Figure 51. Europe Neuroendocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 52. Europe Neuroendocrine Tumor Drug Sales Share by Application (2021-2032) Figure 53. Europe Neuroendocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 54. Europe Neuroendocrine Tumor Drug Sales Share by Country (2021-2032) Figure 55. China Neuroendocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 56. China Neuroendocrine Tumor Drug Sales Share by Type (2021-2032) Figure 57. China Neuroendocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 58. China Neuroendocrine Tumor Drug Sales Share by Application (2021-2032) Figure 59. Asia Neuroendocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 60. Asia Neuroendocrine Tumor Drug Sales Share by Type (2021-2032) Figure 61. Asia Neuroendocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 62. Asia Neuroendocrine Tumor Drug Sales Share by Application (2021-2032) Figure 63. Asia Neuroendocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 64. Asia Neuroendocrine Tumor Drug Sales Share by Country (2021-2032) Figure 65. SAMEA Neuroendocrine Tumor Drug Revenue Share by Type (2021-2032) Figure 66. SAMEA Neuroendocrine Tumor Drug Sales Share by Type (2021-2032) Figure 67. SAMEA Neuroendocrine Tumor Drug Revenue Share by Application (2021-2032) Figure 68. SAMEA Neuroendocrine Tumor Drug Sales Share by Application (2021-2032) Figure 69. SAMEA Neuroendocrine Tumor Drug Revenue Share by Country (2021-2032) Figure 70. SAMEA Neuroendocrine Tumor Drug Sales Share by Country (2021-2032) Figure 71. Neuroendocrine Tumor Drug Value Chain Figure 72. Manufacturing Cost Structure Figure 73. Neuroendocrine Tumor Drug Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Years Considered Figure 77. Research Process Figure 78. Key Executives Interviewed

Scope & coverage.

Types
  • mTOR Protein Inhibitors
  • Tyrosine Kinase 3 Inhibitors
  • Growth Hormone Releasing Factor Antagonists
  • Somatostatin Receptor Agonists
  • Somatostatin Receptor Antagonists
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Exelixis, Inc.
  • Foresee Pharmaceuticals, LLC
  • Hutchison MediPharma Limited
  • Intezyne, Inc
  • INVENT Pharmaceuticals, Inc.
  • Ipsen S.A.
  • Karyopharm Therapeutics, Inc.
  • Lexicon Pharmaceuticals, Inc.
  • Midatech Pharma Plc .
  • Millennium Pharmaceuticals, Inc.
  • MolMed S.p.A.
  • Northwest Biotherapeutics, Inc.
  • OctreoPharm Sciences GmbH
  • OXiGENE, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Novartis AG
  • Eisai

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Neuroendocrine Tumor Drug Market by Type
  3. 1.2.1 Global Neuroendocrine Tumor Drug Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 mTOR Protein Inhibitors
  5. 1.2.3 Tyrosine Kinase 3 Inhibitors
  6. 1.2.4 Growth Hormone Releasing Factor Antagonists
  7. 1.2.5 Somatostatin Receptor Agonists
  8. 1.2.6 Somatostatin Receptor Antagonists
  9. 1.2.7 Others
  10. 1.3 Neuroendocrine Tumor Drug Market by Application
  11. 1.3.1 Global Neuroendocrine Tumor Drug Market Size by Application, 2021 VS 2025 VS 2032
  12. 1.3.2 Hospital
  13. 1.3.3 Clinic
  14. 1.3.4 Others
  15. 1.4 Assumptions and Limitations
  16. 1.5 Study Goals and Objectives
2 Neuroendocrine Tumor Drug Market Dynamics
  1. 2.1 Neuroendocrine Tumor Drug Industry Trends
  2. 2.2 Neuroendocrine Tumor Drug Industry Drivers
  3. 2.3 Neuroendocrine Tumor Drug Industry Opportunities and Challenges
  4. 2.4 Neuroendocrine Tumor Drug Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Neuroendocrine Tumor Drug Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Neuroendocrine Tumor Drug Revenue by Region
  3. 3.2.1 Global Neuroendocrine Tumor Drug Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Neuroendocrine Tumor Drug Revenue by Region (2021-2026)
  5. 3.2.3 Global Neuroendocrine Tumor Drug Revenue by Region (2027-2032)
  6. 3.2.4 Global Neuroendocrine Tumor Drug Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Neuroendocrine Tumor Drug Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Neuroendocrine Tumor Drug Sales by Region
  9. 3.4.1 Global Neuroendocrine Tumor Drug Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Neuroendocrine Tumor Drug Sales by Region (2021-2026)
  11. 3.4.3 Global Neuroendocrine Tumor Drug Sales by Region (2027-2032)
  12. 3.4.4 Global Neuroendocrine Tumor Drug Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Neuroendocrine Tumor Drug Revenue by Manufacturers
  2. 4.1.1 Global Neuroendocrine Tumor Drug Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Neuroendocrine Tumor Drug Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Neuroendocrine Tumor Drug Sales by Manufacturers
  6. 4.2.1 Global Neuroendocrine Tumor Drug Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Neuroendocrine Tumor Drug Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Neuroendocrine Tumor Drug Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Neuroendocrine Tumor Drug Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Neuroendocrine Tumor Drug Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Neuroendocrine Tumor Drug Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Neuroendocrine Tumor Drug Manufacturers, Product Type & Application
  13. 4.7 Global Neuroendocrine Tumor Drug Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Neuroendocrine Tumor Drug Market CR5 and HHI
  16. 4.8.2 2025 Neuroendocrine Tumor Drug Tier 1, Tier 2, and Tier 3
5 Neuroendocrine Tumor Drug Market by Type
  1. 5.1 Global Neuroendocrine Tumor Drug Revenue by Type
  2. 5.1.1 Global Neuroendocrine Tumor Drug Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Neuroendocrine Tumor Drug Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Neuroendocrine Tumor Drug Sales by Type
  6. 5.2.1 Global Neuroendocrine Tumor Drug Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Neuroendocrine Tumor Drug Sales by Type (2021-2032) & (W Units)
  8. 5.2.3 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2021-2032)
  9. 5.3 Global Neuroendocrine Tumor Drug Price by Type
6 Neuroendocrine Tumor Drug Market by Application
  1. 6.1 Global Neuroendocrine Tumor Drug Revenue by Application
  2. 6.1.1 Global Neuroendocrine Tumor Drug Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Neuroendocrine Tumor Drug Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Neuroendocrine Tumor Drug Sales by Application
  6. 6.2.1 Global Neuroendocrine Tumor Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Neuroendocrine Tumor Drug Sales by Application (2021-2032) & (W Units)
  8. 6.2.3 Global Neuroendocrine Tumor Drug Sales Market Share by Application (2021-2032)
  9. 6.3 Global Neuroendocrine Tumor Drug Price by Application
7 Company Profiles
  1. 7.1 Exelixis, Inc.
  2. 7.1.1 Exelixis, Inc. Company Information
  3. 7.1.2 Exelixis, Inc. Business Overview
  4. 7.1.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolio
  6. 7.1.5 Exelixis, Inc. Recent Developments
  7. 7.2 Foresee Pharmaceuticals, LLC
  8. 7.2.1 Foresee Pharmaceuticals, LLC Company Information
  9. 7.2.2 Foresee Pharmaceuticals, LLC Business Overview
  10. 7.2.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolio
  12. 7.2.5 Foresee Pharmaceuticals, LLC Recent Developments
  13. 7.3 Hutchison MediPharma Limited
  14. 7.3.1 Hutchison MediPharma Limited Company Information
  15. 7.3.2 Hutchison MediPharma Limited Business Overview
  16. 7.3.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolio
  18. 7.3.5 Hutchison MediPharma Limited Recent Developments
  19. 7.4 Intezyne, Inc
  20. 7.4.1 Intezyne, Inc Company Information
  21. 7.4.2 Intezyne, Inc Business Overview
  22. 7.4.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolio
  24. 7.4.5 Intezyne, Inc Recent Developments
  25. 7.5 INVENT Pharmaceuticals, Inc.
  26. 7.5.1 INVENT Pharmaceuticals, Inc. Company Information
  27. 7.5.2 INVENT Pharmaceuticals, Inc. Business Overview
  28. 7.5.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  30. 7.5.5 INVENT Pharmaceuticals, Inc. Recent Developments
  31. 7.6 Ipsen S.A.
  32. 7.6.1 Ipsen S.A. Company Information
  33. 7.6.2 Ipsen S.A. Business Overview
  34. 7.6.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolio
  36. 7.6.5 Ipsen S.A. Recent Developments
  37. 7.7 Karyopharm Therapeutics, Inc.
  38. 7.7.1 Karyopharm Therapeutics, Inc. Company Information
  39. 7.7.2 Karyopharm Therapeutics, Inc. Business Overview
  40. 7.7.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  42. 7.7.5 Karyopharm Therapeutics, Inc. Recent Developments
  43. 7.8 Lexicon Pharmaceuticals, Inc.
  44. 7.8.1 Lexicon Pharmaceuticals, Inc. Company Information
  45. 7.8.2 Lexicon Pharmaceuticals, Inc. Business Overview
  46. 7.8.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  48. 7.8.5 Lexicon Pharmaceuticals, Inc. Recent Developments
  49. 7.9 Midatech Pharma Plc .
  50. 7.9.1 Midatech Pharma Plc . Company Information
  51. 7.9.2 Midatech Pharma Plc . Business Overview
  52. 7.9.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolio
  54. 7.9.5 Midatech Pharma Plc . Recent Developments
  55. 7.10 Millennium Pharmaceuticals, Inc.
  56. 7.10.1 Millennium Pharmaceuticals, Inc. Company Information
  57. 7.10.2 Millennium Pharmaceuticals, Inc. Business Overview
  58. 7.10.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolio
  60. 7.10.5 Millennium Pharmaceuticals, Inc. Recent Developments
  61. 7.11 MolMed S.p.A.
  62. 7.11.1 MolMed S.p.A. Company Information
  63. 7.11.2 MolMed S.p.A. Business Overview
  64. 7.11.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  65. 7.11.4 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolio
  66. 7.11.5 MolMed S.p.A. Recent Developments
  67. 7.12 Northwest Biotherapeutics, Inc.
  68. 7.12.1 Northwest Biotherapeutics, Inc. Company Information
  69. 7.12.2 Northwest Biotherapeutics, Inc. Business Overview
  70. 7.12.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  71. 7.12.4 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolio
  72. 7.12.5 Northwest Biotherapeutics, Inc. Recent Developments
  73. 7.13 OctreoPharm Sciences GmbH
  74. 7.13.1 OctreoPharm Sciences GmbH Company Information
  75. 7.13.2 OctreoPharm Sciences GmbH Business Overview
  76. 7.13.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  77. 7.13.4 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolio
  78. 7.13.5 OctreoPharm Sciences GmbH Recent Developments
  79. 7.14 OXiGENE, Inc.
  80. 7.14.1 OXiGENE, Inc. Company Information
  81. 7.14.2 OXiGENE, Inc. Business Overview
  82. 7.14.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  83. 7.14.4 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolio
  84. 7.14.5 OXiGENE, Inc. Recent Developments
  85. 7.15 Jiangsu Hengrui Medicine Co., Ltd.
  86. 7.15.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
  87. 7.15.2 Jiangsu Hengrui Medicine Co., Ltd. Business Overview
  88. 7.15.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  89. 7.15.4 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolio
  90. 7.15.5 Jiangsu Hengrui Medicine Co., Ltd. Recent Developments
  91. 7.16 Novartis AG
  92. 7.16.1 Novartis AG Company Information
  93. 7.16.2 Novartis AG Business Overview
  94. 7.16.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  95. 7.16.4 Novartis AG Neuroendocrine Tumor Drug Product Portfolio
  96. 7.16.5 Novartis AG Recent Developments
  97. 7.17 Eisai
  98. 7.17.1 Eisai Company Information
  99. 7.17.2 Eisai Business Overview
  100. 7.17.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2021-2026)
  101. 7.17.4 Eisai Neuroendocrine Tumor Drug Product Portfolio
  102. 7.17.5 Eisai Recent Developments
8 North America
  1. 8.1 North America Neuroendocrine Tumor Drug Market Size by Type
  2. 8.1.1 North America Neuroendocrine Tumor Drug Revenue by Type (2021-2032)
  3. 8.1.2 North America Neuroendocrine Tumor Drug Sales by Type (2021-2032)
  4. 8.1.3 North America Neuroendocrine Tumor Drug Price by Type (2021-2032)
  5. 8.2 North America Neuroendocrine Tumor Drug Market Size by Application
  6. 8.2.1 North America Neuroendocrine Tumor Drug Revenue by Application (2021-2032)
  7. 8.2.2 North America Neuroendocrine Tumor Drug Sales by Application (2021-2032)
  8. 8.2.3 North America Neuroendocrine Tumor Drug Price by Application (2021-2032)
  9. 8.3 North America Neuroendocrine Tumor Drug Market Size by Country
  10. 8.3.1 North America Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Neuroendocrine Tumor Drug Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
9 Europe
  1. 9.1 Europe Neuroendocrine Tumor Drug Market Size by Type
  2. 9.1.1 Europe Neuroendocrine Tumor Drug Revenue by Type (2021-2032)
  3. 9.1.2 Europe Neuroendocrine Tumor Drug Sales by Type (2021-2032)
  4. 9.1.3 Europe Neuroendocrine Tumor Drug Price by Type (2021-2032)
  5. 9.2 Europe Neuroendocrine Tumor Drug Market Size by Application
  6. 9.2.1 Europe Neuroendocrine Tumor Drug Revenue by Application (2021-2032)
  7. 9.2.2 Europe Neuroendocrine Tumor Drug Sales by Application (2021-2032)
  8. 9.2.3 Europe Neuroendocrine Tumor Drug Price by Application (2021-2032)
  9. 9.3 Europe Neuroendocrine Tumor Drug Market Size by Country
  10. 9.3.1 Europe Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Neuroendocrine Tumor Drug Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Netherlands
  18. 9.3.9 Nordic Countries
10 China
  1. 10.1 China Neuroendocrine Tumor Drug Market Size by Type
  2. 10.1.1 China Neuroendocrine Tumor Drug Revenue by Type (2021-2032)
  3. 10.1.2 China Neuroendocrine Tumor Drug Sales by Type (2021-2032)
  4. 10.1.3 China Neuroendocrine Tumor Drug Price by Type (2021-2032)
  5. 10.2 China Neuroendocrine Tumor Drug Market Size by Application
  6. 10.2.1 China Neuroendocrine Tumor Drug Revenue by Application (2021-2032)
  7. 10.2.2 China Neuroendocrine Tumor Drug Sales by Application (2021-2032)
  8. 10.2.3 China Neuroendocrine Tumor Drug Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Neuroendocrine Tumor Drug Market Size by Type
  2. 11.1.1 Asia Neuroendocrine Tumor Drug Revenue by Type (2021-2032)
  3. 11.1.2 Asia Neuroendocrine Tumor Drug Sales by Type (2021-2032)
  4. 11.1.3 Asia Neuroendocrine Tumor Drug Price by Type (2021-2032)
  5. 11.2 Asia Neuroendocrine Tumor Drug Market Size by Application
  6. 11.2.1 Asia Neuroendocrine Tumor Drug Revenue by Application (2021-2032)
  7. 11.2.2 Asia Neuroendocrine Tumor Drug Sales by Application (2021-2032)
  8. 11.2.3 Asia Neuroendocrine Tumor Drug Price by Application (2021-2032)
  9. 11.3 Asia Neuroendocrine Tumor Drug Market Size by Country
  10. 11.3.1 Asia Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Neuroendocrine Tumor Drug Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Neuroendocrine Tumor Drug Market Size by Type
  2. 12.1.1 SAMEA Neuroendocrine Tumor Drug Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Neuroendocrine Tumor Drug Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Neuroendocrine Tumor Drug Price by Type (2021-2032)
  5. 12.2 SAMEA Neuroendocrine Tumor Drug Market Size by Application
  6. 12.2.1 SAMEA Neuroendocrine Tumor Drug Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Neuroendocrine Tumor Drug Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Neuroendocrine Tumor Drug Price by Application (2021-2032)
  9. 12.3 SAMEA Neuroendocrine Tumor Drug Market Size by Country
  10. 12.3.1 SAMEA Neuroendocrine Tumor Drug Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Neuroendocrine Tumor Drug Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Neuroendocrine Tumor Drug Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Neuroendocrine Tumor Drug Value Chain Analysis
  2. 13.1.1 Neuroendocrine Tumor Drug Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Neuroendocrine Tumor Drug Production Mode & Process
  6. 13.2 Neuroendocrine Tumor Drug Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Neuroendocrine Tumor Drug Distributors
  9. 13.2.3 Neuroendocrine Tumor Drug Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst